As previously reported, BofA analyst Alec Stranahan upgraded Vir Biotechnology (VIR) to Buy from Neutral with a price target of $14, up from $12, arguing that the market is underestimating the potential for its asset for treatment of severe liver disease caused by hepatitis delta virus. There also seems to be minimal value attributed to T-cell engager oncology programs, despite initial proof-of-concept data, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIR:
- Vir Biotechnology upgraded to Buy from Neutral at BofA
- Vir Biotechnology’s Strategic Advancements and Strong Pipeline Drive Buy Rating
- Vir Biotechnology: Strong Execution and Promising Prospects Justify Buy Rating
- Vir Biotechnology’s Earnings Call Highlights Progress and Challenges
- Vir Biotechnology’s Strong Clinical Pipeline and Financial Position Reinforce Buy Rating